<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886206</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0357</org_study_id>
    <nct_id>NCT04886206</nct_id>
  </id_info>
  <brief_title>Phase I Study Testing the Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>ILDA</acronym>
  <official_title>Phase I Study Testing the Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with high risk AML non eligible for an intensive treatment and for an allogeneic&#xD;
      transplantation will be treated with azacitidine and venetoclax. The fourth, fifth and sixth&#xD;
      injection of azacitidine will be followed by injection of haplo-identical lymphocytes (HLI).&#xD;
      This is a single-center phase I study to identify the dose of HLI with the most tolerable&#xD;
      toxicity. TheBayesian continuous reassessment method (CRM) will be used&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Continual Reassessment Method for MTD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of DLT</measure>
    <time_frame>by day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 YEAR</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DLI</intervention_name>
    <description>the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  patients with de novo or secondary AML, with an unfavorable or intermediate karyotype&#xD;
             (according to the 2017 ELN classification), or patients with relapsing AML who may&#xD;
             receive second-line treatment&#xD;
&#xD;
          -  not candidates for intensive induction, for the following reasons&#xD;
&#xD;
               -  75 years or ≥ 18 to 74 years and at least one of the following comorbidities: PS&#xD;
                  ≥ 2 or a history of heart failure requiring treatment or LVEF ≤ 50% or chronic&#xD;
                  stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or creatinine clearance &lt;45 ml / min;&#xD;
                  or liver damage with total bilirubin&gt; 1.5 N or other comorbidities that the&#xD;
                  hematologist considers incompatible with intensive treatment&#xD;
&#xD;
          -  ineligible for a classic allogeneic hematopoietic stem cell transplant due to the&#xD;
             presence of co-morbidities or too high a risk of toxicity &gt;70 years old or at least&#xD;
             one of the following comorbidities: PS ≥ 2 or a history of heart failure requiring&#xD;
             treatment or LVEF ≤ 50% or chronic stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or&#xD;
             creatinine clearance &lt;45 ml / min; or liver damage with total bilirubin&gt; 1.5 N&#xD;
&#xD;
          -  may receive chemotherapy with hypomethylating agents have a partially compatible&#xD;
             (haplo-identical) major family donor (≥18 years old) eligible for lymphocyte donation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AML with favorable karyotype (according to ELN 2017) in RC1&#xD;
&#xD;
          -  Patient with refractory or progressive AML&#xD;
&#xD;
          -  Other progressive cancer in progress&#xD;
&#xD;
          -  Karnosky index &lt;60% or PS&gt; 2&#xD;
&#xD;
          -  Severe hepatic function disturbance: transaminases&gt; 5 N, hyperbilirubinemia&gt; 30 µm / L&#xD;
&#xD;
          -  Severe infection requiring hospitalization.&#xD;
&#xD;
          -  Psychiatric illness compromising the understanding of the information or the carrying&#xD;
             out of the study.&#xD;
&#xD;
          -  woman of childbearing potential and refusing an effective method of contraception.&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Adult under tutorship or curatorship, under legal protection or under family&#xD;
             authorization&#xD;
&#xD;
          -  Minor family donor (&lt;18 years old)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Guillaume</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Guillaume</last_name>
    <phone>02 40 08 49 45</phone>
    <email>thierry.guillaume@chu-nantes.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

